stockrow
Friday 6 November 2026
Export SRRK’s income statement to Excel — free account
Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
46.94
1.44
+3.16%
Follow SRRK
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
5.96 | 6.63 | 8.05 | 6.81 | |
Current Ratio |
6.30 | 6.95 | 8.64 | 7.02 | |
Net Debt/EBITDA |
2.60 | 2.93 | 2.78 | 2.72 | |
Debt/Assets |
24.19% | 24.66% | 36.73% | 37.48% | |
Debt/Equity |
0.41 | 0.41 | 0.71 | 0.77 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 0.83 | 0.78 | 0.64 | |
Capex/Depreciation |
0.40 | (0.10) | (0.34) | 0.00 | |
Interest Coverage |
(77.62) | (36.25) | (44.32) | (24.10) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.61) | (0.66) | (0.65) | (0.54) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.61) | (0.66) | (0.65) | (0.54) | |
Cash per Share |
3.25 | 3.20 | 3.77 | 3.77 | |
Shareholders Equity per Share |
2.15 | 2.14 | 2.17 | 1.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.15 | 2.14 | 2.17 | 1.94 | |
Free Cash Flow |
(69.01) | (75.53) | (82.17) | (70.31) | |
Working Capital |
328.74 | 329.73 | 455.64 | 434.94 | |
Capital Expenditures |
(0.08) | (0.03) | (0.07) | 0.00 | |
Net Current Asset Value |
223.99 | 226.36 | 256.04 | 237.42 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.42 | 10.20 | 6.83 | 6.05 | |
Average Assets |
295.43 | 439.60 | 471.40 | 431.79 | |
Average Common Equity |
162.10 | 307.06 | 294.17 | 243.54 |
Columns are period end dates · fundamentals updated 25 Oct 2026